These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36688247)

  • 21. Dose tapering of dupilumab in patients with persistently controlled atopic dermatitis: a Spanish multicenter cohort study.
    Lasheras-Pérez MA; Palacios-Diaz RD; González-Delgado VA; Cobreros LV; Pereira-Resquin Galván GO; Miquel-Miquel J; Labrandero Hoyos C; Zaragoza Ninet V; Melgosa Ramos FJ; Sánchez-Motilla JM; Navarro-Blanco F; Martín-Torregrosa D; Botella-Estrada R; Rodríguez-Serna M
    Int J Dermatol; 2024 Mar; 63(3):402-404. PubMed ID: 38229523
    [No Abstract]   [Full Text] [Related]  

  • 22. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.
    Bieber T; Simpson EL; Silverberg JI; Thaçi D; Paul C; Pink AE; Kataoka Y; Chu CY; DiBonaventura M; Rojo R; Antinew J; Ionita I; Sinclair R; Forman S; Zdybski J; Biswas P; Malhotra B; Zhang F; Valdez H;
    N Engl J Med; 2021 Mar; 384(12):1101-1112. PubMed ID: 33761207
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reanalysis Following Removal of Participants From 1 Site in Multicenter Trial of Upadacitinib vs Dupilumab for Atopic Dermatitis.
    Blauvelt A
    JAMA Dermatol; 2024 Mar; 160(3):370. PubMed ID: 38353963
    [No Abstract]   [Full Text] [Related]  

  • 24. Dupilumab prevents flares in adults with moderate to severe atopic dermatitis in a 52-week randomized controlled phase 3 trial.
    Merola JF; Sidbury R; Wollenberg A; Chen Z; Zhang A; Shumel B; Rossi AB
    J Am Acad Dermatol; 2021 Feb; 84(2):495-497. PubMed ID: 32387659
    [No Abstract]   [Full Text] [Related]  

  • 25. Impact of comorbidities in the response of atopic patients treated with dupilumab: a real-life study up to 36 weeks.
    Mastorino L; Cantafio Duò VL; Vecco C; Gelato F; Giordano S; Roccuzzo G; Cavaliere G; Avallone G; Ortoncelli M; Ribero S; Quaglino P
    J Eur Acad Dermatol Venereol; 2022 Dec; 36(12):e1021-e1023. PubMed ID: 35841298
    [No Abstract]   [Full Text] [Related]  

  • 26. A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis.
    Volf EM; Au SC; Dumont N; Scheinman P; Gottlieb AB
    J Drugs Dermatol; 2012 Mar; 11(3):341-6. PubMed ID: 22395585
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND).
    Shi VY; Bhutani T; Fonacier L; Deleuran M; Shumack S; Valdez H; Zhang F; Chan GL; Cameron MC; Yin NC
    J Am Acad Dermatol; 2022 Aug; 87(2):351-358. PubMed ID: 35439608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial.
    Reich K; Thyssen JP; Blauvelt A; Eyerich K; Soong W; Rice ZP; Hong HC; Katoh N; Valenzuela F; DiBonaventura M; Bratt TA; Zhang F; Clibborn C; Rojo R; Valdez H; Kerkmann U
    Lancet; 2022 Jul; 400(10348):273-282. PubMed ID: 35871814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-life long-term efficacy of dupilumab in adults with moderate to severe atopic dermatitis: Results of a cohort study.
    Guédon C; Tauber M; Linder C; Paul C; Shourick J
    Ann Dermatol Venereol; 2023 Sep; 150(3):215-216. PubMed ID: 37598014
    [No Abstract]   [Full Text] [Related]  

  • 30. Dupilumab use in atopic dermatitis and beyond in skin diseases.
    Fourzali K; Golpanian RS; Yosipovitch G
    Immunotherapy; 2020 Dec; 12(17):1221-1235. PubMed ID: 32892674
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of dupilumab in a 5-month-old infant with severe atopic dermatitis.
    Havele SA; Khurana MC; McMahon P; Murthy AS; Perman MJ; Treat JR
    Pediatr Dermatol; 2022 Mar; 39(2):291-294. PubMed ID: 35434859
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS.
    Silverberg JI; Yosipovitch G; Simpson EL; Kim BS; Wu JJ; Eckert L; Guillemin I; Chen Z; Ardeleanu M; Bansal A; Kaur M; Rossi AB; Graham NMH; Patel N; Gadkari A
    J Am Acad Dermatol; 2020 Jun; 82(6):1328-1336. PubMed ID: 32135208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 104-week safety and effectiveness of dupilumab in the treatment of severe atopic dermatitis. The experience of 5 reference dermatology units in Spain.
    Pereyra-Rodriguez JJ; Dominguez-Cruz J; Armario-Hita JC; Ruiz-Villaverde R
    An Bras Dermatol; 2021; 96(6):787-790. PubMed ID: 34593266
    [No Abstract]   [Full Text] [Related]  

  • 34. Reported Pregnancy Outcomes in Women With Severe Atopic Dermatitis Treated With Dupilumab: A Systematic Review.
    Akuffo-Addo E; Nicholas MN; Lansang P
    J Cutan Med Surg; 2023; 27(2):177-178. PubMed ID: 36721993
    [No Abstract]   [Full Text] [Related]  

  • 35. Efficacy of Dupilumab for Severe Atopic Dermatitis Co-occurring With Asthma in a Real-World Setting.
    Pose K; Laorden D; Hernández N; Villamañán E; Quirce S; Domínguez-Ortega J
    J Investig Allergol Clin Immunol; 2023 Jun; 33(3):217-219. PubMed ID: 37318773
    [No Abstract]   [Full Text] [Related]  

  • 36. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
    Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
    Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapid disappearance of both severe atopic dermatitis and cold urticaria following dupilumab treatment.
    Ferrucci S; Benzecry V; Berti E; Asero R
    Clin Exp Dermatol; 2020 Apr; 45(3):345-346. PubMed ID: 31437869
    [No Abstract]   [Full Text] [Related]  

  • 38. Switching from dupilumab to tralokinumab in patients with atopic dermatitis due to inefficacy or side effects.
    Lasheras-Pérez MA; Palacios-Diaz RD; Pozuelo-Ruiz M; Torres-Navarro I; Botella-Estrada R; Rodriguez-Serna M
    Int J Dermatol; 2024 Jan; 63(1):105-107. PubMed ID: 38014601
    [No Abstract]   [Full Text] [Related]  

  • 39. Dupilumab provides rapid and sustained improvement in SCORAD outcomes in adults with moderate-to-severe atopic dermatitis: combined results of four randomized phase 3 trials.
    Barbarot S; Wollenberg A; Silverberg JI; Deleuran M; Pellacani G; Armario-Hita JC; Chen Z; Shumel B; Eckert L; Gadkari A; Lu Y; Rossi AB
    J Dermatolog Treat; 2022 Feb; 33(1):266-277. PubMed ID: 32347763
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dupilumab Treatment Reduces Hospitalizations in Adults With Moderate-to-Severe Atopic Dermatitis.
    Silverberg JI; Rubini NPM; Pires MC; Rossi AB; Zhang A; Chen Z; Levit NA; Chao J; Shumel B; Bégo-Le Bagousse G
    J Allergy Clin Immunol Pract; 2022 May; 10(5):1279-1285.e1. PubMed ID: 35032695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.